Compare Abeona Therapeutics Inc (ABEO) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nuscale Power Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Nuscale Power Corporation trades at $8.67 (market cap $3.10B). The key difference: Nuscale Power Corporation is far larger — about 8.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | SMR | |
|---|---|---|
Market Cap | $373.32M | $3.10B |
Sector | Health | Utilities |
52-Week High | $7.23 | $53.43 |
52-Week Low | $4.17 | $8.96 |
Enterprise Value | $228.22M | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NuScale Power (SMR) trades at $9.61, down 1.54% on the day, reflecting ongoing bearish technical momentum. The company shows severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61 million in 2025. Despite this, analyst consensus remains optimistic with a $13.00 price target, and recent news highlights potential long-term growth from SMR technology commercialization and partnerships like ENTRA1.
The outlook is highly speculative; significant upside exists if NuScale successfully commercializes its reactors by the 2030s, but near-term risks include persistent losses, high cash burn, and execution hurdles. Investors face substantial volatility with the stock near its 52-week low, requiring high risk tolerance for potential multi-bagger returns amid operational and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
